Edgar Filing: Onconova Therapeutics, Inc.

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Bienen Henry S

2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2013

3. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc. [ONTX]

(Last)

(First)

(Middle)

C/O ONCONOVA THERAPEUTICS, INC.,Â 375 PHEASANT RUN

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

NEWTOWN,Â PAÂ 18940

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series I Convertible Preferred Stock	Â ⁽¹⁾	Â ⁽¹⁾	Common Stock	9,156	$ ⁽¹⁾	D	Â
Stock Option (right to purchase)	01/01/2010	01/02/2019	Common Stock	4,576	$ 5.76	D	Â
Stock Option (right to purchase)	01/16/2009	01/17/2019	Common Stock	375	$ 5.76	D	Â
Stock Option (right to purchase)	01/01/2011	01/02/2020	Common Stock	4,576	$ 5.76	D	Â
Stock Option (right to purchase)	01/01/2010	01/02/2020	Common Stock	375	$ 5.76	D	Â
Stock Option (right to purchase)	01/01/2012	01/01/2021	Common Stock	4,576	$ 6.13	D	Â
Stock Option (right to purchase)	12/31/2012	01/01/2022	Common Stock	4,726	$ 6.13	D	Â
Stock Option (right to purchase)	01/26/2012	01/26/2022	Common Stock	412	$ 6.13	D	Â
Stock Option (right to purchase)	02/01/2012	02/01/2022	Common Stock	412	$ 6.13	D	Â
Stock Option (right to purchase)	06/21/2012	06/22/2022	Common Stock	412	$ 7.53	D	Â
Stock Option (right to purchase)	07/03/2012	07/04/2022	Common Stock	412	$ 7.53	D	Â
Stock Option (right to purchase)	10/03/2012	10/04/2022	Common Stock	412	$ 13.28	D	Â
Stock Option (right to purchase)	12/17/2012	12/18/2022	Common Stock	412	$ 13.28	D	Â
Stock Option (right to purchase)	01/01/2014	01/02/2023	Common Stock	5,026	$ 13.28	D	Â
Stock Option (right to purchase)	01/01/2013	01/02/2023	Common Stock	7,501	$ 13.28	D	Â
Stock Option (right to purchase)	02/01/2013	02/02/2023	Common Stock	450	$ 13.28	D	Â
Stock Option (right to purchase)	03/14/2013	03/15/2023	Common Stock	450	$ 13.28	D	Â
Stock Option (right to purchase)	04/22/2013	04/23/2023	Common Stock	450	$ 14.74	D	Â
Stock Option (right to purchase)	04/26/2013	04/27/2023	Common Stock	450	$ 14.74	D	Â
Stock Option (right to purchase)	06/07/2013	06/08/2023	Common Stock	450	$ 14.74	D	Â
Stock Option (right to purchase)	06/11/2013	06/12/2023	Common Stock	450	$ 14.74	D	Â
Stock Option (right to purchase)	06/17/2013	06/18/2023	Common Stock	450	$ 14.74	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Bienen Henry S C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN,Â PAÂ 18940	Â X	Â	Â	Â

Signatures

/s/ Ajay Bansal, as attorney in fact		07/24/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.